A risk grouping algorithm for predicting factors of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.

Abstract

After radical prostatectomy, prostate-specific antigen(PSA) value measuring ≥0.1ng/mL is defined as persistent PSA(pPSA) and in many studies, it was found to be associated with aggressive disease and poor prognosis. Our aim in this study is to point out the pathological and clinical factors affecting pPSA among the patients who underwent robot-assisted radical prostatectomy(RARP) in an experienced academic centre and to make a useful risk grouping algorithm that can predict pPSA value based on operative data. We examined records of 1273 patients who underwent RARP retrospectively. Preoperative, operative and postoperative data were collected. Based on the PSA values (ng/mL) measured after 4-to-8weeks of RARP, patients were divided into two groups as pPSA group (Group1)(n=97) with PSA values ≥0.1ng/mL and undetectable PSA group (Group2)(n=778) with PSA values <0.1ng/mL. Later on, Group1 was further divided into Group1a (PSA:0.1-0.2ng/mL) and Group 1b (PSA≥0.2ng/mL) to evaluate biochemical recurrence(BCR). Multivariate logistic regression analyses of the collected data revealed that preoperative PSA≥20ng/mL, operation time, a postoperative international society of urological pathology (ISUP) grade of ≥4, pT 3-4 and pN were independently associated with pPSA. Based on these results, a risk grouping algorithm predicting pPSA was developed. By looking at the risk grouping algorithm pPSA was found in 98.9% of the cases with a preoperative PSA value of ≥20ng/mL, an operation time of 150min, a postoperative ISUP grade of 4-5, a positive lymphovascular invasion (LVI) status, pT3-T4, and pN+; while pPSA was found in 25.5% of the cases with a preoperative PSA value of <20ng/mL, an operation time of 100min, a postoperative ISUP grade of <4-5, a negative LVI status, pT<3-4 and pN-. The estimated BCR-free survival time was 16.3months in Group 1a and 57.0months in Group2 (P<.001). Adjuvant treatment ratio was 64.9% in Group1 and 7.1% in Group2 (P<.001). For the patients who underwent RARP, factors associated with aggressive disease can predict the PSA persistence. To plan our treatment modalities accurately, an applicable risk grouping algorithm in daily practice would be useful.